Ankylosing spondylitis is painful, often significantly so. In large studies of patients living with the condition, the median pain score is 5 out of 10, and roughly 27% of patients report pain levels above 7 out of 10. The pain is chronic, inflammatory, and behaves differently from ordinary back pain, which is part of what makes it so disruptive to daily life.
What the Pain Feels Like
The hallmark of ankylosing spondylitis is inflammatory back pain, which has a distinct pattern. It typically starts gradually in the lower back and hips, feels worst first thing in the morning or after sitting still for a while, and improves with movement and exercise. This is the opposite of most back injuries, where rest helps and activity makes things worse. Many people with the condition are woken up at night by pain and then feel stiff for at least 30 minutes after getting out of bed, sometimes much longer.
The stiffness is not just mild tightness. The muscles running along the spine become chronically stiff from sustained inflammation, limiting flexibility in ways that make bending, turning, and even deep breathing difficult. Over time, this morning ritual of slowly loosening up becomes a defining feature of the disease.
Where the Pain Occurs
Pain usually starts at the sacroiliac joints, the two joints where the base of the spine meets the pelvis. From there it can spread up through the lumbar spine and eventually into the mid and upper back. But ankylosing spondylitis is not limited to the spine. It also targets entheses, the points where tendons and ligaments attach to bone. Common sites include the heels, the bottoms of the feet, and the areas around the ribs, hips, and shoulders.
Enthesitis, the inflammation at these attachment points, is particularly uncomfortable because it creates a deep, localized ache that flares with pressure or use. The immune system floods these areas with inflammatory proteins called cytokines, which cause swelling and pain. Over time, those same cytokines can trigger abnormal bone growth at the inflamed sites, forming bone spurs that create additional mechanical pain on top of the inflammation.
Some people also experience eye inflammation (uveitis), which causes sudden eye pain, redness, and light sensitivity. Chest wall pain from inflammation where the ribs meet the spine or breastbone can make it painful to take a full breath. These extra-spinal symptoms add unpredictable layers of pain that many people don’t initially connect to their back condition.
How Pain Changes Over Time
Left untreated, the disease tends to progress in a specific direction: chronic inflammation gradually triggers new bone formation. Bony bridges called syndesmophytes grow along the edges of the vertebrae, and over decades, these can fuse sections of the spine together. About 40% of patients eventually develop complete spinal fusion. The process is typically slow, taking many years, but the nature of pain shifts along the way. Early on, the pain is primarily inflammatory, driven by active immune attacks. As structural damage accumulates, mechanical pain from lost mobility and abnormal posture layers on top of or replaces the inflammatory pain.
This progression matters because inflammatory pain responds well to treatment, while structural damage is largely permanent. The earlier the disease is caught, the more effectively pain can be managed and damage prevented.
Why Diagnosis Takes So Long
One of the most frustrating aspects of ankylosing spondylitis is how long it takes to get a diagnosis. The average delay from first symptoms to diagnosis is nearly 8 years. People who have enthesitis as an early symptom wait even longer, averaging close to 9 years. During that time, patients often cycle through general practitioners and orthopedic specialists who treat the pain as ordinary back trouble.
This delay has real consequences. Research shows that longer diagnostic delays correlate with worse disease activity scores, greater loss of spinal mobility, reduced quality of life, and more functional impairment. Years of uncontrolled inflammation allow structural damage to accumulate before appropriate treatment ever begins.
How Severe the Pain Gets
Disease activity in ankylosing spondylitis is tracked using a patient-reported scale called the BASDAI, scored from 0 to 10. A score of 4 or higher is considered active disease. In community studies, the median BASDAI score is 4.8, and nearly 79% of patients score 4 or above. About 16% score above 7, representing severe, poorly controlled disease. These numbers reflect patients going about their daily lives, not just those in hospital settings. The pain burden in the general population of people with the condition is high.
For comparison, people with ordinary non-inflammatory back pain in the same studies had a median BASDAI of 2.7, with only about 3% scoring above 7. The gap illustrates how much more disabling the inflammatory process is compared to common mechanical back pain.
The Mental Health Toll
Living with chronic pain of this nature takes a measurable psychological toll. A meta-analysis found that roughly 29% of people with ankylosing spondylitis experience depression, and about 35% experience anxiety. Compared to the general population, people with the condition have a 51% higher risk of developing depression and an 85% higher risk of anxiety. The relationship runs in both directions: pain drives depression and anxiety, and those mental health conditions amplify the perception of pain, creating a cycle that’s harder to break the longer it continues.
How Treatment Affects Pain
The good news is that modern treatments can dramatically reduce pain for many people. Anti-inflammatory medications are typically the first step, and regular exercise and physical therapy are consistently effective at managing stiffness. For people whose pain doesn’t respond to these approaches, biologic medications that target specific inflammatory pathways can make a striking difference.
In one study tracking patients on biologic therapy, the average disease activity score dropped from 4.1 at baseline to 1.2 after just three months. By three years, it had fallen to 0.5, representing near-remission levels. These medications work by blocking the inflammatory proteins responsible for both pain and structural damage, addressing the root cause rather than just masking symptoms.
Not everyone responds equally, and some patients continue to experience significant pain despite treatment. But the trajectory for most people who receive an accurate diagnosis and appropriate therapy is substantially better than the natural course of the disease. The key variable is time: the sooner treatment starts, the less damage accumulates and the more effectively pain can be controlled.